Back to Search Start Over

Role and targeting of anaplastic lymphoma kinase in cancer

Authors :
Floriana Morgillo
Giuseppe Viscardi
Teresa Troiani
Fortunato Ciardiello
Raimondo Di Liello
Carminia Maria Della Corte
Morena Fasano
Erika Martinelli
Della Corte, Carminia Maria
Viscardi, Giuseppe
Di Liello, Raimondo
Fasano, Morena
Martinelli, Erika
Troiani, Teresa
Ciardiello, Fortunato
Morgillo, Floriana
Source :
Molecular Cancer, Molecular Cancer, Vol 17, Iss 1, Pp 1-9 (2018)
Publication Year :
2018
Publisher :
BioMed Central, 2018.

Abstract

Anaplastic lymphoma kinase (ALK) gene activation is involved in the carcinogenesis process of several human cancers such as anaplastic large cell lymphoma, lung cancer, inflammatory myofibroblastic tumors and neuroblastoma, as a consequence of fusion with other oncogenes (NPM, EML4, TIM, etc) or gene amplification, mutation or protein overexpression. ALK is a transmembrane tyrosine kinase receptor that, upon ligand binding to its extracellular domain, undergoes dimerization and subsequent autophosphorylation of the intracellular kinase domain. When activated in cancer it represents a target for specific inhibitors, such as crizotinib, ceritinib, alectinib etc. which use has demonstrated significant effectiveness in ALK-positive patients, in particular ALK-positive non- small cell lung cancer. Several mechanisms of resistance to these inhibitors have been described and new strategies are underway to overcome the limitations of current ALK inhibitors.

Details

Language :
English
ISSN :
14764598
Volume :
17
Database :
OpenAIRE
Journal :
Molecular Cancer
Accession number :
edsair.doi.dedup.....936e02cc8e185d6105186ac67a855b3c